The legal history of mifepristone in the United States of America. How medical abortion is (partially) filling in the gaps lacking protection after the Supreme Court’s overturn of Roe

Autori

  • Marianna Bergamaschi

DOI:

https://doi.org/10.15168/2284-4503-3468

Parole chiave:

Reproductive rights, medical abortion, mifepristone, Supreme Court, judicial review

Abstract

After the Dobbs landmark decision restored the power to regulate and ban abortion to individual states in 2022, the Supreme Court was called to address reproductive rights once again in 2024. In Food and Drugs Administration v. Alliance for Hippocratic Medicine, anti-abortion groups and some medical professionals demanded a declaration of illegitimacy for mifepristone, the drug used for medication abortions, along with the regulatory framework of the drug, established and updated through time by the Food and Drug Administration (FDA). Although the Justices recognized that the plaintiffs lacked standing without delving into the case’s merits, the importance of scientific evaluations in judicial reasoning is an increasingly relevant matter.

##submission.downloads##

Pubblicato

2025-05-08

Come citare

1.
Bergamaschi M. The legal history of mifepristone in the United States of America. How medical abortion is (partially) filling in the gaps lacking protection after the Supreme Court’s overturn of Roe. BioLaw [Internet]. 8 maggio 2025 [citato 8 giugno 2025];(1):115-29. Available at: https://teseo.unitn.it/biolaw/article/view/3468

Fascicolo

Sezione

Call for papers